In partnership with a leading pharmaceutical research institute, FAST Nano Lab demonstrated the ability of FAST Technology to stabilize poorly soluble oncology actives such as paclitaxel and docetaxel. The study showed significant improvements in dispersion uniformity and shelf-life without using surfactants or lipid carriers—marking a milestone for low-solubility cancer therapeutics.